“Our inclusion in the DelveInsight report reinforces our conviction that AQR‑008 has the potential to be a disruptive innovation in cardiovascular therapy,” said Michael Fole, MD, Chief Executive Officer of Aqur Biosciences.

The full report is available for purchase at: https://www.delveinsight.com/report-store/pcsk9-inhibitors-market

About Aqur Biosciences, Inc.:

Headquartered in Westlake Village, California, Aqur Biosciences, Inc. is dedicated to revolutionizing high cholesterol treatment. Aqur is advancing AQR-008, an innovative oral PCSK9 inhibitor, with the potential to substantially reduce LDL cholesterol and mitigate the risk of cardiovascular diseases such as heart attack and stroke.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intend,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Readers are cautioned not to put undue reliance on forward-looking statements, except as required by law. Aqur assumes no obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.